Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Prostate Cancer

Free Subscription Articles published in Am J Clin Oncol Retrieve available abstracts of 12 articles: HTML format Text format

Single Articles

March 2019
1. DEN RB, George D, Pieczonka C, McNamara M, et al
   Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection.
   Am J Clin Oncol. 2019 Mar 4. doi: 10.1097/COC.0000000000000528.
   PubMed     Text format     Abstract available
   
   
   February 2019
2. STEIN MN, Chen YH, Carducci MA, Hudes GR, et al
   Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805).
   Am J Clin Oncol. 2019 Feb 15. doi: 10.1097/COC.0000000000000526.
   PubMed     Text format     Abstract available
   
   
   
3. FOSTER B, Jackson W, Foster C, Dess R, et al
   Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy: Implications for Treatment Optimization.
   Am J Clin Oncol. 2019 Feb 4. doi: 10.1097/COC.0000000000000521.
   PubMed     Text format     Abstract available
   
   
   January 2019
4. RICE SR, Olexa G, Hussain A, Mannuel H, et al
   A Phase II Study Evaluating Bone Marrow-Sparing, Image-guided Pelvic Intensity-Modulated Radiotherapy (IMRT) With Cesium-131 Brachytherapy Boost, Adjuvant Chemotherapy, and Long-Term Hormonal Ablation in Patients With High Risk, Nonmetastatic Prostate
   Am J Clin Oncol. 2019 Jan 22. doi: 10.1097/COC.0000000000000520.
   PubMed     Text format     Abstract available
   
   
   September 2018
5. WALE DJ, Viglianti BL, Gross MD, Ferretti A, et al
   Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma.
   Am J Clin Oncol. 2018 Sep 10. doi: 10.1097/COC.0000000000000479.
   PubMed     Text format     Abstract available
   
   
   April 2018
6. SATKUNASIVAM R, Lo M, Stern M, Gill IS, et al
   The Role of Provider Characteristics in the Selection of Surgery or Radiation for Localized Prostate Cancer and Association With Quality of Care Indicators.
   Am J Clin Oncol. 2018 Apr 17. doi: 10.1097/COC.0000000000000442.
   PubMed     Text format     Abstract available
   
   
   March 2018
7. J BLEDSOE T, S Park H, E Rutter C, Aneja S, et al
   Impact of Health Insurance Status on Prostate Cancer Treatment Modality Selection in the United States.
   Am J Clin Oncol. 2018 Mar 7. doi: 10.1097/COC.0000000000000423.
   PubMed     Text format     Abstract available
   
   
   January 2018
8. TRAN S, Jorcano S, Falco T, Lamanna G, et al
   Oligorecurrent Nodal Prostate Cancer: Long-term Results of an Elective Nodal Irradiation Approach.
   Am J Clin Oncol. 2018 Jan 8. doi: 10.1097/COC.0000000000000419.
   PubMed     Text format     Abstract available
   
   
   
9. KANG JJ, Reiter RE, Kummer N, DeKernion J, et al
   Wrong to be Right: Margin Laterality is an Independent Predictor of Biochemical Failure After Radical Prostatectomy.
   Am J Clin Oncol. 2018;41:1-5.
   PubMed     Text format     Abstract available
   
   
   December 2017
10. YING J, Wang CJ, Yan J, Liauw SL, et al
    Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy.
    Am J Clin Oncol. 2017;40:612-620.
    PubMed     Text format     Abstract available
    
    
    
11. LAWRENCE YR, Samueli B, Levitin R, Pail O, et al
    Do Prostate Cancer Patients With Markedly Elevated PSA Benefit From Radiation Therapy?: A Population-based Study.
    Am J Clin Oncol. 2017;40:605-611.
    PubMed     Text format     Abstract available
    
    
    May 2017
12. SHAVERDIAN N, Kishan AU, Veruttipong D, Demanes DJ, et al
    Impact of the Primary Information Source Used for Decision Making on Treatment Perceptions and Regret in Prostate Cancer.
    Am J Clin Oncol. 2017 May 23. doi: 10.1097/COC.0000000000000387.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: